Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis

OBJECTIVE: Sodium glucose cotransporter type 2 inhibitors (SGLT-2i) are beneficial for cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM), heart failure (HF) or chronic kidney disease (CKD). However, whether or not the patients with coronary artery disease (CAD) have prognostic be...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wen, Liu, Jin, Chen, Shiqun, Xu, Xinghao, Guo, Dachuan, He, Yibo, Huang, Zhidong, Wang, Bo, Huang, Haozhang, Li, Qiang, Chen, Jiyan, Chen, Hong, Tan, Ning, Liu, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940298/
https://www.ncbi.nlm.nih.gov/pubmed/35330914
http://dx.doi.org/10.3389/fendo.2022.850836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940298/
https://www.ncbi.nlm.nih.gov/pubmed/35330914
http://dx.doi.org/10.3389/fendo.2022.850836

Ejemplares similares